Interleukin-17 Promotes the Production of Underglycosylated IgA1 in DAKIKI Cells

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2018 Jan 5

PMID 29299950

Citations 16

Authors

Jia-Ru Lin

Ji Wen

Hui Zhang

Li Wang

Fang-Fang Gou

Man Yang

Jun-Ming Fan

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin 17 (IL-17) plays an important role in the pathogenesis of autoimmune diseases and might be associated with IgA nephropathy (IgAN). This study aimed to investigate the effect of IL-17 on autoimmune pathogenesis in IgA nephropathy.

Methods: DAKIKI cells were cultured and stimulated with IL-17 to perform dose-dependent and time-dependent experiments. Cell proliferation was examined by cell counting and the Cell Counting Kit-8 (CCK-8) assay. The IgA concentration and the degree of galactosylation in the supernatant were tested using ELISA and a helix aspersa (HAA) lectin binding assay, respectively. To study the mechanism of O-glycosylation, cells were stimulated with IL-17, lipopolysaccharide (LPS) or 5-azacytidine (5-AZA) + IL-17 for 48 h, and the levels of C1GALT1 and its molecular chaperone Cosmc were measured by western blot and real-time PCR.

Results: The cell counting and CCK-8 results suggested that B lymphocyte proliferation increased significantly with increased IL-17 concentration. IL-17 affected the quantity of IgA1 and its glycosylation status. HAA revealed that IL-17 promoted IgA1 underglycosylation. Mechanistically, the expression of C1GALT1 and Cosmc was significantly lower in cells stimulated by IL-17 or LPS than in the 5-AZA + IL-17 or the control group.

Conclusions: Our results suggested that IL-17 stimulates B lymphocyte to promote B-cell proliferation, which leads to increased IgA1 production in vitro accompanied by underglycosylation of IgA1. The molecular mechanism for the IgA1 underglycosylation induced by IL-17 was similar to that of LPS; however, 5-AZA inhibited IgA1 underglycosylation. IL-17 might participate in IgAN pathogenesis by influencing the production and glycosylation of IgA1 in B-cells.

Citing Articles

Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis.

Li M, Hao X, Shi D, Cheng S, Zhong Z, Cai L Front Med. 2024; 18(5):862-877.

PMID: 39343836 DOI: 10.1007/s11684-024-1086-2.

Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy.

Fan Y, Wang Y, Xiao H, Sun H BMC Nephrol. 2024; 25(1):203.

PMID: 38907188 PMC: 11191200. DOI: 10.1186/s12882-024-03646-3.

Pharmacological targets of SGLT2 inhibitors on IgA nephropathy and membranous nephropathy: a mendelian randomization study.

Lv X, Shang Y, Ning Y, Yu W, Wang J Front Pharmacol. 2024; 15:1399881.

PMID: 38846092 PMC: 11155304. DOI: 10.3389/fphar.2024.1399881.

Combined Genetic Association and Differed Expression Analysis of Uncovers a Genetic Regulatory Role of (Immuno)proteasome in IgA Nephropathy.

Xu L, Gan T, Li Y, Chen P, Shi S, Liu L Kidney Dis (Basel). 2024; 10(3):167-180.

PMID: 38835407 PMC: 11149991. DOI: 10.1159/000537987.

Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients.

Uriol-Rivera M, Obrador-Mulet A, Julia M, Daza-Cajigal V, Delgado-Sanchez O, Garcia Alvarez A Sci Rep. 2024; 14(1):4866.

PMID: 38418932 PMC: 10902332. DOI: 10.1038/s41598-024-55425-7.

References

McKenzie B, Kastelein R, Cua D . Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2005; 27(1):17-23. DOI: 10.1016/j.it.2005.10.003. View

Matsumoto K, Kanmatsuse K . Interleukin-17 stimulates the release of pro-inflammatory cytokines by blood monocytes in patients with IgA nephropathy. Scand J Urol Nephrol. 2003; 37(2):164-71. DOI: 10.1080/00365590310008929. View

He L, Peng Y, Liu H, Yin W, Chen X, Peng X . Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol. 2013; 38(4):321-32. DOI: 10.1159/000355393. View

Hashimoto A, Suzuki Y, Suzuki H, Ohsawa I, Brown R, Hall S . Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol. 2012; 181(4):1338-47. PMC: 3463632. DOI: 10.1016/j.ajpath.2012.06.038. View

Honorati M, Neri S, Cattini L, Facchini A . Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage. 2005; 14(4):345-52. DOI: 10.1016/j.joca.2005.10.004. View

Matsumoto K, Kanmatsuse K . Increased urinary excretion of interleukin-17 in nephrotic patients. Nephron. 2002; 91(2):243-9. DOI: 10.1159/000058399. View

Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, Kitagawa M . Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010; 136(3):447-55. DOI: 10.1016/j.clim.2010.05.009. View

Xie L, Qin W, Fan J, Huang J, Xie X, Li Z . The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clin Invest Med. 2010; 33(1):E5-13. DOI: 10.25011/cim.v33i1.11832. View

Bettelli E, Oukka M, Kuchroo V . T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007; 8(4):345-50. DOI: 10.1038/ni0407-345. View

10.

Stangou M, Bantis C, Skoularopoulou M, Korelidou L, Kouloukouriotou D, Scina M . Th1, Th2 and Treg/T17 cytokines in two types of proliferative glomerulonephritis. Indian J Nephrol. 2016; 26(3):159-66. PMC: 4862260. DOI: 10.4103/0971-4065.159303. View

11.

Weckert H, Hughes J, Benson E, Dunn I . Quantifiable analysis of human immunoglobulin heavy chain class-switch recombination to all isotypes. J Immunol Methods. 2000; 233(1-2):141-58. DOI: 10.1016/s0022-1759(99)00132-5. View

12.

Zhang Z, Wang H, Zhang L, Crew R, Zhang N, Liu X . Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy. J Immunol Res. 2016; 2016:6540937. PMC: 5120178. DOI: 10.1155/2016/6540937. View

13.

Serino G, Sallustio F, Cox S, Pesce F, Schena F . Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol. 2012; 23(5):814-24. PMC: 3338289. DOI: 10.1681/ASN.2011060567. View

14.

Lin F, Jiang G, Shan J, Zhu C, Zou J, Wu X . Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest. 2012; 72(3):221-9. DOI: 10.3109/00365513.2011.652158. View

15.

Xie L, Tan C, Fan J, Fu P, Tang Y, Tao Y . Mycophenolic acid reverses IgA1 aberrant glycosylation through up-regulating Cosmc expression in IgA nephropathy. Int Urol Nephrol. 2012; 45(2):571-9. DOI: 10.1007/s11255-012-0313-y. View

16.

Yu L, Peng C, Starnes S, Liou R, Chang T . Two isoforms of human membrane-bound alpha Ig resulting from alternative mRNA splicing in the membrane segment. J Immunol. 1990; 145(11):3932-6. View

17.

Xiang S, Benson E, Dunn I . Tracking membrane and secretory immunoglobulin alpha heavy chain mRNA variation during B-cell differentiation by real-time quantitative polymerase chain reaction. Immunol Cell Biol. 2001; 79(5):472-81. DOI: 10.1046/j.1440-1711.2001.01033.x. View

18.

Qin W, Zhong X, Fan J, Liu X, Li Z, Ma X . [Effect of methylation modification on the expression of Cosmc gene in peripheral B lymphocyte of IgA nephropathy patients]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012; 42(6):762-5. View

19.

DAmico G . Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36(2):227-37. DOI: 10.1053/ajkd.2000.8966. View

20.

Qin W, Zhong X, Fan J, Zhang Y, Liu X, Ma X . External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant. 2008; 23(5):1608-14. DOI: 10.1093/ndt/gfm781. View